TherapeuticsMD (TXMD) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart

TherapeuticsMD Revenue Highlights

Latest Revenue (Y)

$1.30M

Main Segment (Y)

License

TherapeuticsMD Revenue by Period

TherapeuticsMD Revenue by Year

Date	Revenue	Change
2023-12-31	$1.30M	-98.14%
2022-12-31	$69.96M	-19.54%
2021-12-31	$86.95M	34.03%
2020-12-31	$64.87M	30.67%
2019-12-31	$49.65M	208.38%
2018-12-31	$16.10M	-4.04%
2017-12-31	$16.78M	-13.32%
2016-12-31	$19.36M	-3.90%
2015-12-31	$20.14M	34.05%
2014-12-31	$15.03M	71.23%
2013-12-31	$8.78M	129.85%
2012-12-31	$3.82M	82.84%
2011-12-31	$2.09M	4230.79%
2010-12-31	$48.22K	356.21%
2009-12-31	$10.57K	100.00%
2008-12-31	-	100.00%
2007-12-31	-	-100.00%
2006-12-31	$1.01M	7.57%
2005-12-31	$934.52K	50.26%
2004-12-31	$621.93K	42.13%
2003-12-31	$437.59K	52.68%
2002-12-31	$286.60K	-13.82%
2001-12-31	$332.57K	-9.63%
2000-12-31	$368.02K	71.82%
1999-12-31	$214.19K	10.42%
1998-12-31	$193.97K	0.45%
1997-12-31	$193.10K	-20.88%
1996-12-31	$244.05K	24.62%
1995-12-31	$195.83K	-0.48%
1994-12-31	$196.78K	-2.19%
1993-12-31	$201.18K	-

TherapeuticsMD generated $1.30M in revenue during NA 2023, up -98.14% compared to the previous quarter, and up 8.09% compared to the same period a year ago.

TherapeuticsMD Revenue by Quarter

Date	Revenue	Change
2024-09-30	-	-100.00%
2024-06-30	$234.00K	-25.24%
2024-03-31	$313.00K	-37.65%
2023-12-31	$502.00K	-1047.17%
2023-09-30	$-53.00K	-112.13%
2023-06-30	$437.00K	5.05%
2023-03-31	$416.00K	-63.89%
2022-12-31	$1.15M	-94.49%
2022-09-30	$20.92M	-26.76%
2022-06-30	$28.56M	47.73%
2022-03-31	$19.33M	3.51%
2021-12-31	$18.68M	-26.48%
2021-09-30	$25.41M	10.46%
2021-06-30	$23.00M	15.78%
2021-03-31	$19.87M	-12.01%
2020-12-31	$22.58M	16.72%
2020-09-30	$19.34M	80.76%
2020-06-30	$10.70M	-12.65%
2020-03-31	$12.25M	-22.96%
2019-12-31	$15.90M	-32.96%
2019-09-30	$23.72M	290.20%
2019-06-30	$6.08M	54.03%
2019-03-31	$3.95M	-22.46%
2018-12-31	$5.09M	46.52%
2018-09-30	$3.47M	-7.69%
2018-06-30	$3.76M	-0.28%
2018-03-31	$3.77M	-8.51%
2017-12-31	$4.12M	-6.64%
2017-09-30	$4.42M	3.93%
2017-06-30	$4.25M	6.65%
2017-03-31	$3.99M	-11.19%
2016-12-31	$4.49M	-18.94%
2016-09-30	$5.54M	25.72%
2016-06-30	$4.40M	-10.69%
2016-03-31	$4.93M	-12.43%
2015-12-31	$5.63M	8.47%
2015-09-30	$5.19M	7.06%
2015-06-30	$4.85M	8.33%
2015-03-31	$4.48M	5.11%
2014-12-31	$4.26M	1.71%
2014-09-30	$4.19M	11.58%
2014-06-30	$3.75M	32.55%
2014-03-31	$2.83M	-1.13%
2013-12-31	$2.86M	24.76%
2013-09-30	$2.29M	10.28%
2013-06-30	$2.08M	35.37%
2013-03-31	$1.54M	23.90%
2012-12-31	$1.24M	19.71%
2012-09-30	$1.04M	26.53%
2012-06-30	$819.15K	13.50%
2012-03-31	$721.69K	-65.40%
2011-12-31	$2.09M	99237.00%
2011-09-30	$2.10K	100.00%
2011-06-30	-	100.00%
2011-03-31	-	-100.00%
2010-12-31	$20.36K	-7.94%
2010-09-30	$22.12K	285.77%
2010-06-30	$5.73K	-62.59%
2010-03-31	$15.33K	45.04%
2009-12-31	$10.57K	100.00%
2009-09-30	-	100.00%
2009-06-30	-	100.00%
2009-03-31	-	100.00%
2008-12-31	-	100.00%
2008-09-30	-	100.00%
2008-06-30	-	100.00%
2008-03-31	-	100.00%
2007-12-31	-	-

TherapeuticsMD generated - in revenue during Q3 2024, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

TherapeuticsMD Revenue Breakdown

TherapeuticsMD Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 23	Dec 22	Dec 21	Dec 18
License	$1.30M	$69.96M	$1.17M	-
Prescription Vitamins	-	-	$5.72M	$15.04M
Annovera	-	-	$37.94M	-
Product	-	-	$85.78M	-
IMVEXXY R	-	-	-	$1.06M

TherapeuticsMD's latest annual revenue breakdown by segment (product or service), as of Dec 23: License (100.00%).

Quarterly Revenue by Product

Product/Service	Sep 24	Jun 24	Mar 24	Mar 23	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Jun 19	Mar 19	Dec 18	Sep 18
License and Service	$547.00K	$234.00K	$313.00K	$416.00K	-	-	-	-	-	-	-	-	-	-	-
License And Service	-	-	-	-	-	$65.00K	$419.00K	-	-	-	-	-	-	-	-
Imvexxy	-	-	-	-	$6.95M	$6.67M	$9.84M	-	-	-	-	-	-	-	-
Annovera	-	-	-	-	$10.41M	$18.27M	$8.51M	$7.83M	$11.81M	$9.55M	-	-	-	-	-
Prescription Vitamins	-	-	-	-	$892.00K	$904.00K	$875.00K	$1.50M	$1.35M	$1.45M	$1.43M	$2.82M	$1.94M	$4.24M	$3.26M
Product	-	-	-	-	$20.92M	$28.50M	$18.91M	$18.68M	$24.47M	$23.00M	$19.63M	-	-	-	-
License	-	-	-	-	-	-	-	-	$937.00K	-	$234.00K	-	-	-	-
Bijuva	-	-	-	-	-	-	-	-	-	$2.16M	-	-	-	-	-
ANNOVERA	-	-	-	-	-	-	-	-	-	-	$8.75M	-	-	-	-
BIJUVA	-	-	-	-	-	-	-	-	-	-	$2.44M	$134.28K	-	-	-
IMVEXXY	-	-	-	-	-	-	-	-	-	-	$7.01M	$3.12M	$2.01M	-	-
IMVEXXY R	-	-	-	-	-	-	-	-	-	-	-	-	-	$846.13K	-
IMVEXXY TM	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$212.08K

TherapeuticsMD's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: License and Service (100.00%).

TherapeuticsMD Revenue Breakdown by Country

Quarterly Revenue by Country

Country	Mar 23	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Jun 19	Mar 19	Dec 18	Sep 18
License and Service	$416.00K	-	-	-	-	-	-	-	-	-	-	-
Imvexxy	-	$6.95M	$6.67M	$9.84M	-	-	-	-	-	-	-	-
Product	-	$20.92M	$28.50M	$18.91M	$18.68M	$24.47M	$23.00M	$19.63M	-	-	-	-
Prescription Vitamins	-	$892.00K	$904.00K	$875.00K	$1.50M	$1.35M	$1.45M	$1.43M	$2.82M	$1.94M	$4.24M	$3.26M
License And Service	-	-	$65.00K	$419.00K	-	-	-	-	-	-	-	-
Annovera	-	$10.41M	$18.27M	$8.51M	$7.83M	$11.81M	$9.55M	-	-	-	-	-
License	-	-	-	-	-	$937.00K	-	$234.00K	-	-	-	-
Bijuva	-	-	-	-	-	-	$2.16M	-	-	-	-	-
ANNOVERA	-	-	-	-	-	-	-	$8.75M	-	-	-	-
IMVEXXY	-	-	-	-	-	-	-	$7.01M	$3.12M	$2.01M	-	-
BIJUVA	-	-	-	-	-	-	-	$2.44M	$134.28K	-	-	-
IMVEXXY R	-	-	-	-	-	-	-	-	-	-	$846.13K	-
IMVEXXY TM	-	-	-	-	-	-	-	-	-	-	-	$212.08K

TherapeuticsMD's latest quarterly revenue breakdown by geography, as of Mar 23: License and Service (100.00%).

TherapeuticsMD Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
PTPI	Petros Pharmaceuticals	$5.82B	$1.42M
ALKS	Alkermes	$1.66B	$378.14M
ANIP	ANI Pharmaceuticals	$486.82M	$148.33M
IRWD	Ironwood Pharmaceuticals	$442.74M	$91.59M
ORGO	Organogenesis	$433.14M	$115.18M
EGRX	Eagle Pharmaceuticals	$316.61M	$64.65M
LFCR	Lifecore Biomedical	$128.26M	$24.70M
AQST	Aquestive Therapeutics	$50.58M	$13.54M
CPIX	Cumberland Pharmaceuticals	$39.55M	$9.09M
TKNO	Alpha Teknova	$36.68M	$9.58M
AGRX	Agile Therapeutics	$19.59M	$5.58M
GHSI	Guardion Health Sciences	$12.25M	$36.35K
EVOK	Evoke Pharma	$5.18M	$2.65M
ADMP	Adamis Pharmaceuticals	$4.76M	$9.06M
TXMD	TherapeuticsMD	$1.30M	-
CYTH	Cyclo Therapeutics	$1.08M	$123.10K
ACRX	Talphera	$651.00K	$117.00K
PRFX	PainReform	-	-

TXMD Revenue FAQ

What is TherapeuticsMD’s yearly revenue?

TherapeuticsMD's yearly revenue for 2023 was $1.3M, representing a decrease of -98.14% compared to 2022. The company's yearly revenue for 2022 was $69.96M, representing a decrease of -19.54% compared to 2021. TXMD's yearly revenue for 2021 was $86.95M, representing an increase of 34.03% compared to 2020.

What is TherapeuticsMD’s quarterly revenue?

TherapeuticsMD's quarterly revenue for Q3 2024 was $0, a -100.00% decrease from the previous quarter (Q2 2024), and a 0% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $234K, a -25.24% decrease from the previous quarter (Q1 2024), and a -46.45% decrease year-over-year (Q2 2023). TXMD's quarterly revenue for Q1 2024 was $313K, a -37.65% decrease from the previous quarter (Q4 2023), and a -24.76% decrease year-over-year (Q1 2023).

What is TherapeuticsMD’s revenue growth rate?

TherapeuticsMD's revenue growth rate for the last 3 years (2021-2023) was -98.50%, and for the last 5 years (2019-2023) was -97.38%.

What are TherapeuticsMD’s revenue streams?

TherapeuticsMD's revenue streams in c 23 are License

What is TherapeuticsMD’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of TherapeuticsMD was License. This segment made a revenue of $1.3M, representing 100.00% of the company's total revenue.